Biosimilars developer Oncobiologics Inc. has landed a $31 million financing to support continued expansion and development of its platform and pipeline, which includes clinical-stage biosimilars of Humira (adalimumab, Abbvie Inc.), Avastin (bevacizumab, Roche AG), and nine other preclinical candidates poised to take on off-patent biologics.